Budesonide + formoterol delivered via Spiromax ® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler ® .

MLA

Lewis, A., et al. “Budesonide + Formoterol Delivered via Spiromax ® for the Management of Asthma and COPD: The Potential Impact on Unscheduled Healthcare Costs of Improving Inhalation Technique Compared with Turbuhaler ® .” Respiratory Medicine, vol. 129, Aug. 2017, pp. 179–88. EBSCOhost, https://doi.org/10.1016/j.rmed.2017.06.018.

APA

Lewis, A., Torvinen, S., Dekhuijzen, P. N. R., Chrystyn, H., Melani, A., Zöllner, Y., Kolbe, K., Watson, A. T., Blackney, M., & Plich, A. (2017). Budesonide + formoterol delivered via Spiromax ® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler ® . Respiratory Medicine, 129, 179–188. https://doi.org/10.1016/j.rmed.2017.06.018

Chicago

Lewis, A, S Torvinen, P N R Dekhuijzen, H Chrystyn, A Melani, Y Zöllner, K Kolbe, A T Watson, M Blackney, and A Plich. 2017. “Budesonide + Formoterol Delivered via Spiromax ® for the Management of Asthma and COPD: The Potential Impact on Unscheduled Healthcare Costs of Improving Inhalation Technique Compared with Turbuhaler ® .” Respiratory Medicine 129 (August): 179–88. doi:10.1016/j.rmed.2017.06.018.